ASCO GI 2024 | TESLA: TG01/QS-21 ± PD-1 inhibitor for MRD in RAS mutated pancreatic cancer

Anup Kasi, MD, MPH, from the University of Kansas Cancer Center, presents a Phase II randomized TESLA trial (NCT05638698) focusing on patients with surgically resected Stage 1-3 RAS mutant pancreatic ductal adenocarcinoma (PDAC) who are minimal residual disease positive (MRD+) after completing standard adjuvant chemotherapy. The trial evaluates the efficacy of the TG01/QS-21 vaccine alone or in combination with balstilimab, a PD-1 inhibitor. MRD is detected using a commercially available circulating tumor DNA (ctDNA) assay, with somatic variants identified through whole-exome sequencing. The treatment schedule involves a priming phase of six vaccine administrations followed by a maintenance phase, with balstilimab administered every two weeks. Imaging assessments occur every 12 weeks. The primary objective is to assess the 6-month molecular disease control rate, while secondary objectives include safety, disease-free survival rates, and correlation between molecular response depth and disease-free survival. Enrollment is ongoing. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.